...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of orthopaedics and traumatology: official journal of the Italian Society of Orthopaedics and Traumatology >Single intra-articular injection of high molecular weight hyaluronic acid for hip osteoarthritis
【24h】

Single intra-articular injection of high molecular weight hyaluronic acid for hip osteoarthritis

机译：关节内单次注射高分子量透明质酸治疗髋骨关节炎

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Intra-articular (IA) injection of hyaluronic acid (HA) into the hip joint appears to be safe and well tolerated but only a small number of randomized clinical trials in humans has been published. The objective of this prospective study was to evaluate the efficacy and safety of a single IA injection of high-molecular-weight (2800 kDa) HA (Coxarthrum) for hip osteoarthritis. All patients received a single IA administration of 2.5 % sodium hyaluronate (75 mg/3 mL) of high molecular weight. Fluoroscopy requires an iodized contrast medium (iopamidol, 1 ml) which highlights the capsule before administering HA. Patients were evaluated before IA injection (T0), after 3 months, after 6 months and after 1 year from injection. Results were evaluated by the Brief Pain Inventory (BPI II), Harris Hip Score and a visual analog scale of pain (pain VAS). All treated patients were considered for statistical analysis. Two hundred seven patients were included at T0. The mean age was 67 years (range 46–81). Regarding BPI severity score, changes in pain between T0 and the three following visits were statistically highly significant (p  0.001). Changes in pain score compared to the previous visit were statistically significant for the worst pain in the second quarter post-intervention (p = 0.037) and for mean pain in the second semester post-intervention (p = 0.043) The evolution of the Harris Hip Score was statistically highly significant (p  0.001) between T0 and the following visits (T0 + 3 months, T0 + 6 months and T0 + 12 months); after a significant change between T0 and T0 + 3 months, the score remained stable. The evolution of the pain VAS showed a statistically highly significant improvement (p  0.001) between T0 and T0 + 3 months; thereafter it remained stable from the first quarter post-intervention. No serious adverse event was noted; 12 cases (0.5 %) of pain associated with transient synovitis are noteworthy. This study shows that a single IA injection of Coxarthrum is effective from the third month and that the results are stable or continue to improve up to 1 year. IV.
机译：关节腔内（IA）向髋关节注射透明质酸（HA）似乎是安全且耐受性良好的，但仅公开了少量的人类随机临床试验。这项前瞻性研究的目的是评估单次IA注射高分子量（2800 kDa）HA（Coxarthrum）对髋骨关节炎的疗效和安全性。所有患者均接受单次IA施用2.5％高分子量透明质酸钠（75 mg / 3 mL）。透视检查需要加碘的造影剂（iopamidol，1 ml），在加HA前先加亮胶囊。 IA注射前（T0），注射后3个月，6个月后和1年后对患者进行评估。通过简短疼痛量表（BPI II），Harris Hip评分和视觉模拟疼痛量表（疼痛VAS）评估结果。考虑所有接受治疗的患者进行统计分析。 T0纳入了277位患者。平均年龄为67岁（范围46-81）。关于BPI严重程度评分，在T0和随后的三次就诊之间的疼痛变化在统计学上具有高度显着性（p <0.001）。干预后第二季度最严重的疼痛（p = 0.037）和干预后第二个学期的平均疼痛（p = 0.043）与上次就诊相比疼痛评分的变化在统计学上具有显着意义在T0和随后的访问（T0 + 3个月，T0 + 6个月和T0 + 12个月）之间，得分在统计上具有高度显着性（p <0.001）;在T0和T0 + 3个月之间有显着变化后，分数保持稳定。在T0和T0 + 3个月之间，疼痛VAS的演变显示出统计学上非常显着的改善（p <0.001）;此后从干预后的第一季度开始保持稳定。没有发现严重的不良事件。值得注意的是12例（0.5％）与短暂性滑膜炎相关的疼痛。这项研究表明，单次IA注射Coxarthrum从第三个月开始有效，结果稳定或持续改善到1年。 IV。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号